Navigation Links
Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
Date:5/15/2012

WILMINGTON, Del., May 15, 2012 /PRNewswire/ -- Butamax™ Advanced Biofuels, LLC announced today that the United States Patent and Trademark Office (USPTO) has granted Butamax Patent Number 8,178,328. The '328 patent covers a highly efficient engineered pathway for producing isobutanol from recombinant microorganisms at commercial scale.  These novel microorganisms have been designed using advanced biotechnology to convert sugar to isobutanol.

(Logo: http://photos.prnewswire.com/prnh/20120209/MM50763LOGO )

The '328 patent also protects extraction and distillation of the isobutanol, as well as steps for recovering the solids (distillers grains) produced during isobutanol fermentation.  Protection of biobutanol processes that produce these grains is key in that distillers grains provide a significant economic advantage for Butamax's customers and provide local agriculture with a high-protein animal feed.  With these added protections having priority back to 2005, the '328 patent extends Butamax's foundational patent estate to span key value drivers for commercialization.

The USPTO granted the '328 patent in view of the art cited against Butamax's '188 and '899 patents in reexamination requests filed by Gevo.  This means that the USPTO has determined that the '328 patent is novel and inventive over all of the publications referenced in reexamination of the '188 and '889 patents.

"Grant of this new patent supports the Butamax view that the USPTO will ultimately affirm the '188 and '889 patents at the conclusion of the re-examination process," said Paul Beckwith, CEO Butamax.

Butamax will add the '328 patent to its ongoing litigation against Gevo.  A decision on Butamax's request for preliminary injunction against Gevo for infringing its '889 patent is expected in the near term and trial for that lawsuit (which also includes the '188 patent) is scheduled for April 2013; subsequent trials are expected for July 2014.

About Butamax

Butamax™ Advanced Biofuels, LLC, a joint venture between BP and DuPont, was formed to develop and commercialize biobutanol as a next generation renewable biofuel for the transport market. The company benefits from the synergy of DuPont's proven industrial biotechnology experience and BP's global fuels market knowledge. Butamax's proprietary technology offers a cost-advantaged manufacturing process for isobutanol with value from field to pump. For more information, visit www.butamax.com.

Butamax™ is a trademark of Butamax™ Advanced Biofuels, LLC.

Media Contact:
Cory Ziskind 646-277-1232


'/>"/>
SOURCE Butamax Advanced Biofuels, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Butamax™ Responds to Gevo Patent Infringement Lawsuit
2. Butamax™ and Fagen Announce Collaboration to Retrofit Ethanol Plants for Biobutanol Production
3. MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process
4. Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements
5. ScinoPharm Granted US Patent for Novel Crystal Forms
6. BioLife Solutions Granted European Biopreservation Patent
7. GeneNews granted U.S. patent for Chagas disease based on Sentinel Principle(TM) platform
8. Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy
9. Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe
10. Crisis Exemption Granted to Market Avipel(R) Corn Seed Treatment in Louisiana
11. VIASPACE Granted US Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading provider ... nationwide oncology Clinical Nurse Educator (CNE) network, which will launch ... for communication among health care professionals to enhance the patient ... office staff, and other health care professionals to help women ... cancer. ...
(Date:10/11/2017)... ... ... Disappearing forests and increased emissions are the main causes of the evolving ... those living in larger cities are affected by air pollution related diseases. , That ... countries globally - decided to take action. , “I knew I had to take ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
(Date:4/6/2017)... 6, 2017 Forecasts by Product ... Readers, by End-Use (Transportation & Logistics, Government & Public ... & Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business ... Are you looking for a definitive report on ... ...
Breaking Biology News(10 mins):